Literature DB >> 12884910

Src family kinases in tumor progression and metastasis.

Justin M Summy1, Gary E Gallick.   

Abstract

The Src family of non-receptor protein tyrosine kinases plays critical roles in a variety of cellular signal transduction pathways, regulating such diverse processes as cell division, motility, adhesion, angiogenesis, and survival. Constitutively activated variants of Src family kinases, including the viral oncoproteins v-Src and v-Yes, are capable of inducing malignant transformation of a variety of cell types. Src family kinases, most notably although not exclusively c-Src, are frequently overexpressed and/or aberrantly activated in a variety of epithelial and non-epithelial cancers. Activation is very common in colorectal and breast cancers, and somewhat less frequent in melanomas, ovarian cancer, gastric cancer, head and neck cancers, pancreatic cancer, lung cancer, brain cancers, and blood cancers. Further, the extent of increased Src family activity often correlates with malignant potential and patient survival. Activation of Src family kinases in human cancers may occur through a variety of mechanisms and is frequently a critical event in tumor progression. Exactly how Src family kinases contribute to individual tumors remains to be defined completely, however they appear to be important for multiple aspects of tumor progression, including proliferation, disruption of cell/cell contacts, migration, invasiveness, resistance to apoptosis, and angiogenesis. This review details the evidence for Src family activation in human tumors, and emphasizes possible consequences to tumor progression. Given the ability of Src and its family members to participate in so many aspects of tumor progression and metastasis, Src family kinases are attractive targets for future anti-cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884910     DOI: 10.1023/a:1023772912750

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  320 in total

1.  p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.

Authors:  Michelle K Y Siu; Hoi Yan Chan; Daniel S H Kong; Esther S Y Wong; Oscar G W Wong; Hextan Y S Ngan; Kar Fai Tam; Hongquan Zhang; Zhilun Li; Queeny K Y Chan; Sai Wah Tsao; Staffan Strömblad; Annie N Y Cheung
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-06       Impact factor: 11.205

2.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

3.  Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.

Authors:  Ke-Jun Liu; Jie-Hua He; Xiao-Dong Su; Hong-May Sim; Jing-Dun Xie; Xing-Gui Chen; Fang Wang; Yong-Ju Liang; Satyakam Singh; Kamlesh Sodani; Tanaji T Talele; Suresh V Ambudkar; Zhe-Sheng Chen; Hai-Ying Wu; Li-Wu Fu
Journal:  Int J Cancer       Date:  2012-06-13       Impact factor: 7.396

4.  Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials.

Authors:  A Black; D Morris
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

Review 5.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

6.  Apoptosis-associated tyrosine kinase 1 inhibits growth and migration and promotes apoptosis in melanoma.

Authors:  Shuang Ma; Brian P Rubin
Journal:  Lab Invest       Date:  2014-03-03       Impact factor: 5.662

7.  Cullin 5 destabilizes Cas to inhibit Src-dependent cell transformation.

Authors:  Anjali Teckchandani; George S Laszlo; Sergi Simó; Khyati Shah; Carissa Pilling; Alexander A Strait; Jonathan A Cooper
Journal:  J Cell Sci       Date:  2013-11-27       Impact factor: 5.285

8.  SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.

Authors:  Yoshihiro Tokuhisa; Michael E Lidsky; Hiroaki Toshimitsu; Ryan S Turley; Georgia M Beasley; Tomio Ueno; Ketan Sharma; Christina K Augustine; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2013-11-27       Impact factor: 5.344

Review 9.  Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Authors:  Michael E Lidsky; Paul J Speicher; Betty Jiang; Masahito Tsutsui; Douglas S Tyler
Journal:  J Surg Oncol       Date:  2013-11-20       Impact factor: 3.454

Review 10.  Src signaling pathways in prostate cancer.

Authors:  Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.